Showing posts with label 177Lu-dotatate extend neuroendocrine tumour PFS. Show all posts
Showing posts with label 177Lu-dotatate extend neuroendocrine tumour PFS. Show all posts
Monday, November 2, 2015

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

›
  Positive progression-free survival (PFS) results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians tr...